NASDAQ$WHWK
Whitehawk Therapeutics Inc · Q2 2021 earnings
Q2 2021 earnings · · Investor relations
Briefing
Aerpio Pharmaceuticals reported financial results for Q2 2021 and provided a business update.
Aerpio Pharmaceuticals reported a net loss of $4.4 million for the three months ended June 30, 2021. The company had $36.8 million in cash and cash equivalents as of June 30, 2021. Aerpio entered into a merger agreement with Aadi Bioscience, Inc. on May 16, 2021.
- Ended second quarter 2021 with $36.8 million in cash and cash equivalents.
- Operating expenses totaled $4.8 million, a decrease of 16.9% compared to $5.7 million for the same period in 2020.
- Research and development expenses decreased approximately 79.7%, to $0.7 million from $3.5 million in the three months ended June 30, 2020.
- Net loss attributable to common stockholders was $4.4 million, or ($0.09) per common share, compared to net income attributable to common stockholders of $9.3 million, or $0.23 per common share, for the same period in 2020.
Headline financials
Revenue & EPS history
Aadi Bioscience · Revenue · Quarterly
$15M
Revenue by segment
Aadi Bioscience · $5.96M total across 1 segment · Q3 2023
- Product Sales, Net$5.96M—100.0%
Forward guidance
This communication contains forward-looking statements based upon our current expectations that involve risks and uncertainties.
Tailwinds
- The combined company’s listing on Nasdaq after the closing of the proposed transaction.
- Statements about the structure, timing and completion of the proposed transaction
- The business of the combined company, including Aadi’s product candidates, the development therefor and the therapeutic potential thereof
- The proposed PIPE and its terms
- The opportunity for Aerpio shareholders to receive value from its legacy assets through the proposed contingent value rights, and the intended benefits from the Aspen’s collaboration with Gossamer Bio for GB004, including the continued development of GB004 and the milestone and royalty payments related to the collaboration.
Headwinds
- Risks associated with Aerpio’s ability to obtain the stockholder approval required to consummate the proposed transaction or to complete the PIPE financing, and the timing of the closing of the proposed transaction
- The response of Aerpio’s stockholders to the proposed transaction
- Risks related to Aerpio’s ability to manage its operating expenses and its expenses associated with the proposed transaction pending closing
- Risks related to the failure or delay in obtaining required approvals from any governmental or quasi-governmental entity necessary to consummate the proposed transaction
- Potential adverse reactions or changes to business relationships resulting from the announcement or completion of the proposed transaction
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2021
+1.8%
Avg return
Earnings day
+2.9%
Avg return
5 days after
+4.1%
Avg return
30 days after
37%
11 / 30 earnings
Positive
+69.8%
Q1 2021
Best reaction
-18.7%
Q1 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -5.3% | -5.5% | -0.7% | |
| Q3 2025 | -0.4% | -3.5% | +10.2% | |
| Q1 2025 | +4.9% | -4.0% | -9.5% | |
| Q4 2024 | -1.5% | +1.2% | +14.7% | |
| Q3 2024 | +5.5% | +5.5% | +21.6% | |
| Q2 2024 | -3.6% | -1.4% | +30.7% | |
| Q1 2024 | -10.9% | -11.4% | -17.5% | |
| Q4 2023 | +5.7% | +9.3% | +1.0% | |
| Q3 2023 | -6.6% | -5.4% | +2.9% | |
| Q2 2023 | -1.0% | +1.7% | -12.2% | |
| Q1 2023 | -18.7% | -17.2% | -4.7% | |
| Q4 2022 | -1.8% | -0.1% | +10.3% | |
| Q3 2022 | +5.1% | +1.2% | +1.7% | |
| Q2 2022 | -6.2% | -0.9% | -11.0% | |
| Q1 2022 | +21.2% | +30.1% | +21.5% | |
| Q4 2021 | +5.4% | +2.3% | -8.2% | |
| Q3 2021 | -16.6% | -8.9% | -13.4% | |
| Q2 2021 | +3.0% | +2.0% | -7.9% | |
| Q1 2021 | +69.8% | +74.1% | +69.0% | |
| Q4 2020 | +1.9% | +2.5% | -15.1% | |
| Q3 2020 | -2.2% | +21.7% | +60.9% | |
| Q2 2020 | +17.3% | +6.4% | -22.4% | |
| Q1 2020 | -0.2% | -1.3% | +82.3% | |
| Q4 2019 | -5.8% | -17.7% | -6.2% | |
| Q3 2019 | -2.6% | -3.6% | +0.9% | |
| Q2 2019 | -1.9% | -1.9% | +0.9% | |
| Q1 2019 | -0.9% | -1.9% | -5.7% | |
| Q4 2018 | +4.2% | +22.4% | -65.0% | |
| Q3 2018 | -1.4% | -11.7% | -2.3% | |
| Q2 2018 | -1.7% | +3.9% | -3.8% | |
| Q4 2011 | — | — | — | |
| Q2 2010 | — | — | — | |
| Q1 2010 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro